The following trials provide information to treat various types of respiratory and inflammatory diseases, both for ongoing and completed clinical trials. For more information on both of these therapy areas please click here.
- collapse An 8-week, randomised, double blind, parallel-group, multi-centre, phase III study comparing the efficacy and safety of Symbicort Turbuhaler 160/4.5 µg twice daily and Pulmicort Turbuhaler 200 µg twice daily + Theolong tablet 200 mg twice daily in Japanese patients with asthma.
- collapse A study to evaluate the feasibility of a treatment algorithm in newly diagnosed asthmatic children. An open follow-up to Asthma Prevention in infants/young children (PAC)
- collapse A naturalistic, prospective, single-center, double-blinded, fixed-dose, randomised, four week comparison study investigating efficacy, tolerability and safety of 200mg per day versus 400mg per day quetiapine fumarate in 200 drug-naïve first-episode psychosis patients aged 15-25 years.
- collapse A Phase I, Open, Randomised, Non-comparative, Parallel Group Study of a Potential Cytochrome P450 3A Induction after Repeat Twice Daily Oral Dosing with 100 and 500 mg AZD1981 Tablets for 14 days to Healthy Male Volunteers with Single Oral Doses of Midazolam 7.5 mg.
- collapse A Phase I open randomized non-comparative parallel group study of potential cytochrome P450 3A induction after repeat twice daily oral dosing with 100 and 500 mg AZD1981 tablets for 14 days to healthy male volunteers with single oral doses of midazolam 7.5 mg
- collapse A randomised placebo-controlled double-blind Phase I study to assess the safety tolerability pharmacokinetics and pharmacodynamics of single and multiple oral doses of AZD1981 in healthy male subjects
- collapse An Open Single-dose Phase I 4-period partly Crossover Study in Healthy Men or Women to Assess Relative Bioavailability of Oral Administration of AZD1981 via Tablets Compared with Suspension and Basic Systemic Pharmacokinetic Parameters after Intravenous Administration
- collapse A Double Blind Placebo Controlled Randomised Parallell Group Phase IIa Study to Evaluate the Histological Changes Cellularity Clinical Efficacy and Safety of AZD1981 in Patients With Moderate to Severe COPD
- collapse A 4 week double-blind placebo-controlled randomised parallel group phase IIa study to assess the efficacy and safety of AZD1981 in patients with moderate to severe COPD
- collapse A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AZD5069 after Single Ascending Doses in Healthy Male and/or Female Subjects.
